Faculty profile

Michael Ong

ResearcherUniversity of Ottawa

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Ottawa directory, so their courses and email address may be missing. Find their university profile.

Michael Ong

Researcher

Health Sciences

University of Ottawa

Ottawa, Ontario, Canada

ORCID

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
25 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

151

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Personal Website Search on Google Scholar iDORCID

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Androgen Deprivation Treatment (Adt)Androgen Receptor Pathway Inhibitors (Arpi)Circulating Tumour Dna (Ctdna)Docetaxel International Metastatic Castration-Sensitive Prostate Cancer Prostate Specific Antigen (Psa)Randomized Controlled Trial

Latest papers

How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?
European urology focus · 2026
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.
Nature communications · 2026
Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation.
Frontiers in oncology · 2026 · senior author

All 55 publications

Latest funding

TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.
CIHR · 2024 · Nominated PI
$2,487,015
The Impact of language on care and outcomes in patients with prostate or breast cancer
CIHR · 2024 · Co-investigator
$100,000
PREPARE for Cancer Surgery Trial: multimodal PReoperative Exercise to decrease PostoperAtive disability, cancer RecurrencE and mortality in older people with frailty
CIHR · 2023 · Co-investigator
$100,000

All 4 grants and awards

55 publications.

How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?

Beauregard JM, Ong M, Pouliot F

European urology focus2026

DOI: 10.1016/j.euf.2026.06.013 PMID: 42336749

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Müller DC, Murtha AJ, Bacon JVW, Stephenson M, Wells C, Vasquez-Rios C, Rostin K, Rebane L, Schönlau E, Nikkola J, Alimohamed N, Basappa NS, Finch D, Ko JJ, Lavoie JM, Nappi L, Noonan K, Ong M, Ozgun G, Parimi S, Soleimani M, Sridhar SS, Toren P, Winquist E, Bernales CQ, Koudjanian M, Atwal J, Fung E, Khan L, Eigl B, Othman D, Bismar TA, Wang G, Merza R, Papadakis AI, Spatz A, Kollmannsberger C, Maurice-Dror C, Annala M, Chi KN, Vandekerkhove G, Wyatt AW, Eigl BJ

Nature communications2026

DOI: 10.1038/s41467-026-69927-7 PMID: 41760649

Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation.

Theriau CF, Maltez N, Hosseini N, Petkiewicz S, Song X, Ong M

Frontiers in oncology2026Senior author

DOI: 10.3389/fonc.2026.1613243 PMID: 41858366

Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study

Ong M, Suzuki H, Smith M, Tombal B, Hussain M, Saad F, Fizazi K, Verholen F, Pham H, Srinivasan S

European Journal of Cancer20262 citationsFirst author

DOI: 10.1016/j.ejca.2026.116264

Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis

Kish EK, Dvorani E, Saskin R, Wilton AS, Satkunasivam R, Aminoltejari K, Hird A, Berscheid K, Roy S, Morgan SC

Current Oncology20261 citations

DOI: 10.3390/curroncol33050276

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir

Ong M, Morash C, Hamilton RJ, Gotto GT, Rendon RA, Malone S, Antebi E, Kolinsky MP, Hotte SJ, N. K

Future Oncology2026First author

DOI: 10.1080/14796694.2026.2665814

Genetic testing practices among specialist physicians who treat prostate cancer: Updated survey of Canadian practitioners

Yip SM, Niazi T, Hamilton RJ, Kolinsky MP, Gotto GT, Hotte SJ, Ong M, Rendon RA, Ferrario C, Saad F

Journal of the Canadian Urological Association2026

DOI: 10.5489/cuaj.9466

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Gambardella V, Ong M, Rodriguez-Ruiz ME, Machiels JP, Sanmamed MF, Galvao V, Spreafico A, Renouf DJ, Luen SJ, Galot R, Doger de Spéville B, Calvo E, Naing A, Curdt S, Kolben TM, Rossmann E, Tanos T, Smart K, Amann M, Xie Y, Xu L, Gomez Alcaide E, Städler N, Justies N, Boetsch C, Karanikas V, Schnetzler G, Rohrberg KS

Cancer research communications2025

DOI: 10.1158/2767-9764.crc-24-0638 PMID: 39983024

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Roy S, Sun Y, Hussain M, Chi KN, Fizazi K, Davis ID, Halabi S, Agarwal N, Chowdhury S, Tombal B, Morgan SC, Malone S, Barata PC, Ong M, Wallis CJD, Berlin A, Swami U, Kishan AU, Jia AY, Zaorsky NG, Garcia JA, Mendiratta P, Brown JR, Subhash VV, Stockler MR, Thomas H, McKay RR, Small EJ, Shore ND, Saad F, Sweeney CJ, Spratt DE

Nature communications2025

DOI: 10.1038/s41467-025-67298-z PMID: 41402322

Canadian Prostate Cancer Trends in the Context of PSA Screening Guideline Changes.

Wilkinson AN, Ellison LF, Zhang SX, Ong M, Morgan SC, Goldenberg SL, Breau RH, Morash C

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol32120669 PMID: 41440197

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2024

Subject: Prospective PhD student: Androgen Deprivation Treatment (Adt) Dear Professor Ong, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?" (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response." (2024), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Michael Ong

Research

Latest papers

Latest funding

How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation.

Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study

Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir

Genetic testing practices among specialist physicians who treat prostate cancer: Updated survey of Canadian practitioners

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Canadian Prostate Cancer Trends in the Context of PSA Screening Guideline Changes.

TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.

The Impact of language on care and outcomes in patients with prostate or breast cancer

PREPARE for Cancer Surgery Trial: multimodal PReoperative Exercise to decrease PostoperAtive disability, cancer RecurrencE and mortality in older people with frailty

PREVENT GU: Prevention of thromboembolism with rivaroxaban in GU cancer patients receiving chemotherapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial

Frequent collaborators

Christina Canil

Bobby Shayegan

Aly-Khan Lalani

Sebastien Hotte

Mark Clemons

Brian Hutton

Antonio Finelli

Eric Winquist

Krista Noonan

Michael Kolinsky

Anna Spreafico

Colleen Webber

Bryan Lo

Gregory Pond

Ilias Cagiannos

Dean Fergusson

Christopher Booth

Peter Tanuseputro

Kim Chi

Neil Fleshner

Wassim Kassouf

Urban Emmenegger

Bruce Burns

David Stewart

John Hilton

Libni Eapen

Robert MacRae

Scott Morgan

Todd Fairhead

Andrew Loblaw

Nancy Maltez

Tracy Stockley

Marie-France Savard

Alexandre Tran

Srikala Sridhar